The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1549
Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
The FDA has approved a fixed-dose combination of meropenem, a carbapenem antibiotic, and vaborbactam, a new beta-lactamase inhibitor (Vabomere – Melinta), for IV treatment of adults with complicated urinary tract infections (UTIs) that are...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Meropenem/Vaborbactam (Vabomere) for Complicated Urinary Tract Infection
Article code: 1549c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.